Safety and efficacy of tazemetostat, an enhancer of zeste-homolog 2 inhibitor, in patients with relapsed or refractory malignant mesothelioma.
Volume
38
Pagination
9058 - 9058
DOI
10.1200/jco.2020.38.15_suppl.9058
Journal
Journal of Clinical Oncology
Issue
ISSN
0732-183X